OR WAIT null SECS
The acquisition of Juniper expands and strengthens Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing.
Catalent, a provider of delivery technologies and development solutions for drugs, biologics, and consumer health products, announced the completion of its previously announced tender offer for all outstanding shares of Juniper Pharmaceuticals at $11.50 per share.
Catalent expects to complete the merger of Catalent Boston into Juniper under Section 251(h) of the Delaware General Corporation Law on Aug. 14, 2018. As a result of the merger, Juniper will become a wholly owned subsidiary of Catalent.
According to Catalent, the acquisition of Juniper expands and strengthens its offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing, and complements its integrated global clinical and commercial supply network.
Juniper provides bioavailability enhancement for poorly soluble compounds, including nano-milling, spray drying, hot-melt extrusion, lipid-based drug delivery, and cGMP clinical manufacturing for potent and controlled substances. Catalent reports that it will continue to support Juniper’s Crinone (progesterone gel) franchise marketed by Merck KGaA outside of the United States.